Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Key facts

Sponsor

Jonsson Comprehensive Cancer Center

Principal Investigator

Ronald Busuttil, md

Jonsson Comprehensive Cancer Center

Intervention

sorafenib tosylate(drug)

Enrollment

20 enrolled

Eligibility

19 years · All sexes

Timeline

2012 – 2023

Study locations (21)

• University of Alabama, Birmingham, Alabama, United States
• Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
• University of Colorado, Denver, Colorado, United States
• Mount Sinai Hospital, Hartford, Connecticut, United States
• Lombardi Comprehensive Cancer Center at Georgetown University, Washington D.C., District of Columbia, United States
• Emory University, Atlanta, Georgia, United States
• Northwestern University, Chicago, Illinois, United States
• Ochsner Clinic Foundation, New Orleans, Louisiana, United States
• Johns Hopkins University, Baltimore, Maryland, United States
• Lahey Clinic Medical Center, Burlington, Massachusetts, United States
• University of Michigan University Hospital, Ann Arbor, Michigan, United States
• University of Nebraska Medical Center, Omaha, Nebraska, United States
• University of Pennsylvania Health System, Cherry Hill, New Jersey, United States
• New York University Langone Medical Center, New York, New York, United States
• New York Presbyterian-The University Hospital of Columbia and Cornell, New York, New York, United States
• +6 more locations on ClinicalTrials.gov

Collaborators

Bayer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07441369
  Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
  Fudan University
• RECRUITINGPHASE2NCT07175441
  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
  Riboscience, LLC.
• RECRUITINGPHASE2NCT07560488
  Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT07291076
  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  Bristol-Myers Squibb
• RECRUITINGPHASE2NCT07010497
  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
  Asan Medical Center
• RECRUITINGPHASE1, PHASE2NCT07500220
  Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
  Beijing Biotech
• RECRUITINGPHASE2NCT07413354
  Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
  Tongji Hospital
• RECRUITINGNANCT07365527
  Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
  Zealand University Hospital

See all trials for Adult hepatocellular carcinoma →